Tag Archives: author

What Will Get Hit Worst When Rates Rise

Summary John Authers argues the assets that will be worst affected by the Fed raising rates are ones paradoxically considered lower risk. These assets are high quality corporate bonds and municipal bonds, particularly those of longer duration. We highlight two bond ETFs that may fit those criteria and offer ways for investors to limit their risk. The Paradox Of Risk In his Long View column in Saturday’s Financial Times (“Dress rehearsals set stage for how assets will react to rate rise”), John Authers pointed out a paradox of risk: Generally, risks are greatest when there are not perceived. People who have bought a security believing it to be high-risk tend to guard themselves against the risk; those who think they have a low-risk investment do not. This could therefore amplify the chance of a full-blown financial “accident.” The putatively low-risk assets Authers has in mind are bonds, specifically higher-quality corporate and municipal bonds of longer duration, and the threat he sees is of the Fed raising rates. How Rising Rates will Hit High Quality Corporates and Munis Although Authers thinks a rate rise this week is unlikely, he sketches out the potential consequences of an eventual series of rate hikes: Higher target rates set by the Fed will send bond yields higher, which means bond prices must go down. With yields already low, the proportionate falls in prices need to be that much greater. Why would high-quality corporate bonds and munis fare worse than other types of bonds? Authers believes that Treasuries will benefit from a flight-to-quality in the event of a rate rise, and junk bonds will be less sensitive to interest rates because they carry greater credit risk. That leaves higher quality corporate bonds and municipal bonds. Authers notes a difference in market structure for bonds that makes the credit market “lumpier” than the stock market: rather than trading on an exchange, most bonds are sold through dealers; and since banks have, since the financial crisis, cut back on the capital they allow their dealers to spend on bonds, there may be fewer institutional buyers to support flagging bond prices. Duration and Interest Rates Bonds vary in their sensitivity to interest rate movements according to factors including their time to maturity. The finance term used to express interest rate sensitivity is duration, and it is expressed as a number of years. The longer a bond’s (or bond ETF’s) duration, the more sensitive it will be to interest rate movements. Two Bond ETFs that May Be at Risk In his column, Authers warned about longer duration bonds, but didn’t quantify what he meant by longer duration. According to Fidelity though, the average duration for fixed income ETFs is 4.43 years. Two ETFs that invest in high quality corporate bonds and municipal bonds, respectively, and have effective durations higher than that are the iShares National AMT-Free Muni Bond ETF (NYSEARCA: MUB ) and the iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSEARCA: LQD ). Both ETFs invest in higher quality bonds. According to its fact sheet , only 0.04% of MUB’s bonds are non-investment grade (BB-rated). The rest are BBB-rated (1.25%), A-rated (28.89%), AA-rated (48.81%) or AAA-rated (21.82%). Its effective duration is 4.75 years. According to LQD’s fact sheet , the bulk of its bonds are either BBB-rated (39.52%) or A-rated (47.68%). The rest are AA-rated (10.8%) or AAA-rated (1.7%). Its effective duration is 8.04 years. Ways For ETF Investors To Limit Their Risk If you own these ETFs, agree with Authers’ thesis, and expect a rate rise sometime in the next several months, there are a couple of ways you can limit your risk. The simplest way is to sell them. If you’d rather not keep your money in cash after selling them, we looked at a low-risk alternative to cash in a recent article (“An Alternative to Cash for a Risk-Averse Investor). Another way to limit your risk if you own these ETFs is to hedge them. You can hedge them by buying optimal puts on the ETFs to limit your downside risk. Puts (short for put options) are contracts that give you the right to sell a security for a specified price (the strike price) before a specified date (the expiration date). Optimal puts are the ones that will give you the level of protection you are looking for at the lowest cost. This page offers more detail on how optimal puts can limit your downside risk. Below are sample hedges for both of the ETFs we’ve discussed here. Hedging LQD against a > 15% decline by March 17th These were the optimal puts, as of Friday’s close, to hedge 1000 shares of LQD against a greater than 15% drop between now and March 17th. As you can see at the bottom of the screen capture above, the cost of this protection, as a percentage of position value, was 0.56%. Note that, to be conservative, this cost was calculated using the ask price of the put options. In practice, you can often purchase put options for less, at some point between the bid and the ask prices. Hedging MUB against a > 15% decline by February 18th These were the optimal puts, as of Friday’s close, to hedge MUB against a greater-than-15% decline between now and February 18th. The cost of protection for the MUB hedge above is 0.41% of position value (calculated in the same conservative manner as above for LQD). It’s not surprising that the LQD hedge is a little more expensive; all else equal, you’d expect it to be a little more expensive because it expires a month later than the MUB hedge. What’s a bit surprising is that it’s not more expensive relative to MUB, given LQD’s lower average credit quality and its significantly higher effective duration. Perhaps the answer is in the paradox of risk offered by Authers: most LQD investors don’t see it as a risky investment, so they haven’t bid up the cost of hedging it. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

IBB: Trees Don’t Grow To The Sky

Summary The collective market capitalization of the biotech index is disconnected from actual sales. Given the huge U.S. Federal deficit (now $18 trillion) and skyrocketing healthcare costs, the costs of biotechnology drugs are unsustainable. The U.S. spends far more than other developed nations for healthcare as a percentage of GDP and on a per capita GDP basis. Unless you are reading the children’s story, Jack and the Beanstalk, the last time I checked, trees don’t grow to the sky. Evidently, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) didn’t get the memo. Let me be clear, I don’t have a science background. So my angle and perspective aren’t derived from actual industry experience or academically grounded. However, as an investor, I don’t need to be able to build the watch, I simply need to tell what time it is. Through a series of charts, common sense, and a general awareness of the world around me, I will lead the reader towards the notion that IBB is priced for perfection. That said, I am not discounting or doubting the remarkable innovation and scientific breakthroughs that are occurring in this gilded age of biotechnological. Rather, I’m simply suggesting the collective valuation is a disconnected sanity. Here are some high level statistics on U.S. healthcare spending. In 2013, U.S. healthcare spending was 17.4% of GDP, or $2.9 trillion. (click to enlarge) Here is a chart comparing per capital spending versus other major industrialized nations: (click to enlarge) Here is another chart depicting spending as a percentage of GDP. As you can clearly see, U.S. spending is off the charts: Source Here are the top holdings within IBB. I also added the rounded market caps. of each top holding (as of September 11, 2015). (click to enlarge) Source: IBB website Although I am much more concerned about IBB than big pharma, I included some of the major pharma names for perspective. The names below cumulatively have $1.7 trillion, that’s with a “T”, in market caps. This doesn’t include their debt as big pharma has been known to issue a lot of low interest rate debt to finance share buybacks and pay sporty dividends. (click to enlarge) Source: Google Finance Over the past five years, IBB has climbed 319% or $270 per share. Wow! (click to enlarge) Source: Google Finance Here is a detailed version of the U.S. healthcare spending: (click to enlarge) Here are the top global drug sales by specific drug and then ranked by the type of therapy area: Source: American Chemical Society Here is why IBB is overvalued and vulnerable to a sharp pullback. Essentially, there is a recognition and ground swell by members of the medical community that drug costs are unsustainable. Given that the government and private health insurers negotiate the prices for these drugs, I’m arguing there will be cost controls and regulatory risks. It is when not if in my mind. Lower-cost generic drugs are on the horizon due to the excessive costs charged by biotechnology companies. These companies have let their greed get the better of them and they may have killed the golden goose. (click to enlarge) Source: WSJ Remember, since 2000, U.S. public debt has grown from $6 trillion to $18 trillion in fifteen years. We have been running deficits every year since the dot-com bubble. Our healthcare costs are at least 600 bps points higher than other industrialized nations and higher on a per capita GDP basis. With the exception of the super-wealthy, the vast majority of people simply can’t afford to buy these expensive medications. (click to enlarge) Andrew Pollack’s NYT article “Drug Prices Soar, Prompting Calls for Justification” published on July 23, 2015, captures this theme poignantly. Here is a direct quote from the article: Pressure is mounting from elsewhere as well. The top Republican and Democrat on the United States Senate Finance Committee last year demanded detailed cost data from Gilead Sciences, whose hepatitis C drugs, which cost $1,000 a pill or more, have strained the budgets of state and federal health programs. The U.A.W. Retiree Medical Benefits Trust tried to make Gilead (NASDAQ: GILD ), Vertex Pharmaceuticals (NASDAQ: VRTX ), Celgene (NASDAQ: CELG ) and other companies report to their shareholders more about how they set prices and the risks to their businesses from resistance to high drug prices. The trust cited the more than $300,000 per year price of Vertex’s cystic fibrosis drug Kalydeco and roughly $150,000 for Celgene’s cancer drug Revlimid. Here is an NPR article with the same theme, “Doctors Press For Action To Lower “Unsustainable” Prices For Cancer Drug.” Here are two direct quotes: “A lot of my patients cry – they’re frustrated,” says Dr. Ayalew Tefferi , a hematologist at the Mayo Clinic. “Many of them spend their life savings on cancer drugs and end up being bankrupt.” The average U.S. family makes $52,000 annually. Cancer drugs can easily cost a $120,000 a year. Out-of-pocket expenses for the insured can run $25,000 to $30,000 – more than half of a typical family’s income. Lastly, written by Robert Pear , here is another NYT article “Health Insurance Companies Seek Big Rate Increases for 2015.” This was published on July 3, 2015. Here is a direct quote from the article: “Health insurance companies around the country are seeking rate increases of 20 percent to 40 percent or more, saying their new customers under the Affordable Care Act turned out to be sicker than expected. Federal officials say they are determined to see that the requests are scaled back.” Conclusion Yes, I understand that 2014 was a great year for purveyors of prescription drugs , with sales climbing 12% at their fastest percentage growth rate since 2002. However, as a society, the political pendulum is tipping towards increased awareness and anger. Given the skyrocketing costs of healthcare, the federal deficits, and the nosebleed market capitalization of biotech stocks relative to sales, it would be prudent to take profits in shares of IBB. The risk greatly outweighs the benefits given the valuations. Remember, trees don’t grow to the sky and $300K drug therapies are unsustainable. Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

ALPS To Launch NextShares Via Turnkey ALPS ETMF Trust

By DailyAlts Staff Denver-based ALPS is the latest company to license Eaton Vance’s NextShares-branded exchange-traded managed funds (“ETMFs”) via Eaton Vance’s Navigate Fund Solutions subsidiary. The agreement between ALPS and Eaton Vance runs both ways, though: The ALPS NextShares ETMFs will be launched through the ALPS ETMF Trust, which is designed to provide turnkey solutions for investment managers looking to launch new NextShares Funds. “It’s clear to us that NextShares can offer certain advantages as vehicles for active investment strategies,” said ALPS CEO Ned Burke, in a recent statement. “As pioneers in product development, we look forward to working with Navigate to bring this new product initiative to the marketplace.” “We believe that the improved performance and tax efficiency of NextShares is what fund investors have been waiting for,” said Stephen W. Clarke, President of Navigate Fund Solutions, in the same press release. “We look forward to working with ALPS to introduce this game-changing idea to investors and the financial advisors who serve them.” NextShares, which received regulatory approval in November 2014, facilitate active management within funds that trade intraday, much like shares of stock. Unlike mutual funds, which can only be bought or sold at the end of each trading day, ETMFs trade when the stock market is open. But unlike ETFs and shares of stock, ETMFs aren’t price in “dollars and cents” per share, but instead, at a premium or discount to the net assets of the fund. This quirk allows ETMF managers to avoid disclosing their holdings on a daily basis, which would undermine active-management performance. ALPS has been steadily growing its presence in the industry in 2015. In April, the firm acquired Red Rocks Capital , a firm specializing in listed private equity funds. Then in July, ALPS launched a pair of equal-weighted (“EW”) ETF products that offered a “twist” on the conventional EW approach by equalizing weightings among sectors. The launch date of ALPS’s first NextShares products is unknown at this time. According to a statement from ALPS, the timing will depend on final regulatory approval and “market readiness.” For more information, visit nextshares.com . Share this article with a colleague